Silexion Therapeutics Statistics
Total Valuation
SLXN has a market cap or net worth of $2.11 million. The enterprise value is $1.29 million.
| Market Cap | 2.11M |
| Enterprise Value | 1.29M |
Important Dates
The last earnings date was Friday, August 14, 2026, before market open.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SLXN has 5.56 million shares outstanding. The number of shares has increased by 2,257.95% in one year.
| Current Share Class | 5.56M |
| Shares Outstanding | 5.56M |
| Shares Change (YoY) | +2,257.95% |
| Shares Change (QoQ) | +112.78% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 0.58% |
| Float | 5.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 48.02 |
| P/TBV Ratio | 48.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 32.05.
| Current Ratio | 0.94 |
| Quick Ratio | 0.56 |
| Debt / Equity | 32.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,086.69 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -5,232.22% |
| Weighted Average Cost of Capital (WACC) | 1.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$997,000 |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -98.92% in the last 52 weeks. The beta is -0.36, so SLXN's price volatility has been lower than the market average.
| Beta (5Y) | -0.36 |
| 52-Week Price Change | -98.92% |
| 50-Day Moving Average | 1.25 |
| 200-Day Moving Average | 10.45 |
| Relative Strength Index (RSI) | 30.24 |
| Average Volume (20 Days) | 8,514,099 |
Short Selling Information
The latest short interest is 14,501, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 14,501 |
| Short Previous Month | 119,287 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.26% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.13M |
| Pretax Income | -13.96M |
| Net Income | -13.96M |
| EBITDA | -14.12M |
| EBIT | -14.13M |
| Earnings Per Share (EPS) | -$38.75 |
Balance Sheet
The company has $2.23 million in cash and $1.41 million in debt, with a net cash position of $819,000 or $0.15 per share.
| Cash & Cash Equivalents | 2.23M |
| Total Debt | 1.41M |
| Net Cash | 819,000 |
| Net Cash Per Share | $0.15 |
| Equity (Book Value) | 44,000 |
| Book Value Per Share | 0.01 |
| Working Capital | -235,000 |
Cash Flow
In the last 12 months, operating cash flow was -$12.43 million and capital expenditures -$2,000, giving a free cash flow of -$12.43 million.
| Operating Cash Flow | -12.43M |
| Capital Expenditures | -2,000 |
| Depreciation & Amortization | 12,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -12.43M |
| FCF Per Share | -$2.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SLXN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,257.95% |
| Shareholder Yield | -2,257.95% |
| Earnings Yield | -660.61% |
| FCF Yield | -588.39% |
Analyst Forecast
The average price target for SLXN is $60.00, which is 15,689.47% higher than the current price. The consensus rating is "Buy".
| Price Target | $60.00 |
| Price Target Difference | 15,689.47% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 29, 2026. It was a reverse split with a ratio of 1:10.
| Last Split Date | May 29, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |